



PRODUCT INFORMATION & MANUAL

Human C-Peptide Valukine™ ELISA

VAL155

For the quantitative determination of natural and recombinant
Human C-Peptide concentrations

For research use only.
Not for diagnostic or therapeutic procedures.

Bio-Techne China Co. Ltd

P: +86 (21) 52380373 P: 8009881270 F: +86 (21) 52381001
info.cn@bio-techne.com

Please refer to the kit label for expiry date.
Novus kits are guaranteed for 3 months from date of receipt

Version202209.2

TABLE OF CONTENTS

I. BACKGROUND	2
II. OVERVIEW	3
III. ADVANTAGES	4
IV. EXPERIMENT	6
V. KIT COMPONENTS AND STORAGE	7
VI. PREPARATION	10
VII. ASSAY PROCEDURE	12
VIII. REFERENCES	14

I. BACKGROUND

Insulin is a peptide hormone that is critical for glucose homeostasis. The mature Insulin peptide is derived from Proinsulin, which includes the Insulin A and B chains connected by a peptide fragment (C-peptide). Proinsulin is processed within the endoplasmic reticulum of pancreatic beta cells into equimolar ratios of mature Insulin and C-peptide. Human C-peptide is a 31 amino acid (aa) peptide that shares 58% and 61% aa sequence identity with the mouse and rat proteins, respectively. Initially, C-peptide was thought to be biologically inactive; however, studies now show that it facilitates microvascular circulation, nerve conduction, and renal function (1).

Upon secretion into the portal circulation, a significant percentage of secreted Insulin is quickly metabolized by the liver. C-peptide is negligibly processed by the liver and can be used as marker of pancreatic beta cell function and endogenous Insulin secretion (2, 3). C-peptide specifically and displaceably binds cell membranes with high affinity and activates an inhibitory G protein (Gi) coupled receptor (4-7). Administration of C-peptide can act in an anti-inflammatory capacity and can lead to improvements in microvascular blood flow and nerve function (4). C-peptide exerts vascular anti-inflammatory effects via the downregulation of endothelial cell surface adhesion molecules, the reduction of inflammatory cytokine production, and the protection of vascular smooth muscle cells from detrimental Insulin effects (8). Alternatively, high concentrations of C-peptide in Type II diabetics may contribute to vascular inflammation associated with atherosclerosis (9). C-peptide administration is associated with increased blood flow to multiple tissues and increases erythrocyte deformability in diabetic individuals (10, 11). It also activates and upregulates eNOS to increase nitric oxide (NO) synthesis, which is known to induce vasodilation (12, 13). Administration of C-peptide is associated with improvements in diabetic neuropathy and may act to increase nerve conduction and prevent neural dysfunction (14, 15). In addition, C-peptide may play a beneficial role in diabetic renal function (16).

II. OVERVIEW

A. PRINCIPLE OF THE ASSAY

This assay employs the quantitative sandwich enzyme immunoassay technique. An antibody specific for human C-Peptide has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any C-Peptide present is bound by the immobilized antibody. After washing away any unbound substances, a biotin-linked detect antibody specific for human C-Peptide are pipetted into the wells. After washing away any unbound substances, streptavidin-HRP are pipetted into the wells. Following a wash to remove any unbound reagent, a substrate solution is added to the wells and color develops in proportion to the amount of C-Peptide bound in the initial step. The color development is stopped, and the intensity of the color is measured.

B. LIMITATIONS OF THE PROCEDURE

- **FOR RESEARCH USE ONLY NOT FOR USE IN DIAGNOSTIC PROCEDURES.**
- This kit is suitable for cell culture supernate and human serum.
- The kit should not be used beyond the expiration date on the kit label.
- Do not mix or substitute reagents with those from other lots or sources.
- If samples generate values higher than the highest standard, dilute the samples with Calibrator Diluent and repeat the assay.
- Any variation in operator, pipetting technique, washing technique, incubation time or temperature, and kit age can cause variation in binding.

III. ADVANTAGES

A. PRECISION

Intra-assay Precision (Precision within an assay)

Three samples were tested twenty times on one plate to assess intra-assay precision.

Inter-assay Precision (Precision between assays)

Three samples were tested in twenty separate assays to assess inter-assay precision.

	Intra-assay Precision			Inter-assay Precision		
Sample	1	2	3	1	2	3
Mean (pg/mL)	38.5	145.7	499.0	38.2	145.9	510.6
Standard Deviation	1.6	6.2	11.6	1.7	6.9	22.7
CV%	4.3	4.3	2.3	4.5	4.7	4.4

B. RECOVERY

The recovery of human C-Peptide spiked to different levels throughout the range of the assay in cell culture media was evaluated. The recovery ranged from 96.5-104.7% with an average of 100.4%.

The recovery of Human C-Peptide spiked to different levels throughout the range of the assay in human serum was evaluated. The recovery ranged from 83.7-99.7% with an average of 92.2%.

C. SENSITIVITY

The minimum detectable dose (MDD) of human C-Peptide is typically less than 0.37 pg/mL.

The MDD was determined by adding two standard deviations to the mean optical density value of twenty zero standard replicates and calculating the corresponding concentration.

D. CALIBRATION

This kit is calibrated against synthetic human Insulin C-Peptide (aa 3-33).

E. LINEARITY

To assess the linearity of the assay, different samples were containing or spiked with high concentrations of human C-Peptide and diluted with Calibrator Diluent (1×) to produce samples with values within the dynamic range of the assay.

Dilution	Average % of Expected	Range (%)
1:2	102.5	93.9-115.7
1:4	103.3	94.5-112.2
1:8	110.0	98.2-117.8
1:16	110.5	97.1-120.7

F. SAMPLE VALUES

Serum - Six human serum samples were evaluated for the presence of human C-Peptide in this assay. All samples measured ranged from n.d. to 544.8 pg/mL.

G. SPECIFICITY


The following factors prepared at 50 ng/mL were assayed and exhibited no cross-reactivity or interference.

Recombinant human	
IGF-I	Relaxin-1
IGF-II	Relaxin-2
Insulin	Relaxin-3
Insulin R	

IV. EXPERIMENT

EXAMPLE STANDARD

The standard curve is provided for demonstration only. A standard curve should be generated for each set of samples assayed.



V. KIT COMPONENTS AND STORAGE

A. MATERIALS PROVIDED

Parts	Description	Size
Human C-Peptide Microplate	96 well polystyrene microplate (12 strips of 8 wells) coated with a Mouse antibody against Human C-Peptide.	1 plate
Human C-Peptide Standard	Recombinant Human C-Peptide in a buffered protein base; lyophilized. Refer to the vial label for reconstitution volume.	2 vials
Human C-Peptide Detection Antibody	Biotinylated C-Peptide antibody, lyophilized. Refer to the vial label for reconstitution volume.	1 vial
Calibrator Diluent (4×)	Concentrated buffered diluent used to dilute standard and samples.	1 vial
Streptavidin-HRP B (40×)	40× Streptavidin conjugated to horseradish peroxidase.	1 vial
Reagent Diluent (10×)	A 10× concentrated buffered protein base used to dilute Detection Antibody and HRP.	1 vial
Wash Buffer Concentrate (25×)	A 25× concentrated solution of buffered surfactant with preservatives.	1 vial
TMB Substrate	TMB ELISA Substrate Solution	1 vial
Stop Solution	2 N sulfuric acid.	1 vial
Plate Sealers	Adhesive strip.	3 strips

B. STORAGE

Unopened Kit	Store at 2-8 °C. Do not use past kit expiration date.	
Opened/ Reconstituted Reagents	Streptavidin-HRP B	May be stored for up to 1 month at 2-8 °C.*
	Diluted Wash Solution	
	TMB Substrate	
	Stop Solution	
	Standard	Prepare fresh for each assay.
	Detection Antibody	Aliquot and store for up to 1 month at -20 °C in a manual defrost freezer. *
	Reagent Diluent (10×)	May be stored for up to 1 month at 2-8 °C.* Use and discard diluted Reagent Diluent (1×). Prepare fresh for each assay.
	Calibrator Diluent (4×)	May be stored for up to 1 month at 2-8 °C.* Use and discard diluted Calibrator Diluent (1×). Prepare fresh for each assay.
Microplate Wells	Return unused wells to the foil pouch containing the desiccant pack, reseal along entire edge of zip-seal. May be stored for up to 1 month at 2-8 °C.*	

* Provided this is within the expiration date of the kit.

C. OTHER SUPPLIES REQUIRED

- ◆ Microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
- ◆ Pipettes and pipette tips.
- ◆ Deionized or distilled water.
- ◆ Squirt bottle, manifold dispenser, or automated microplate washer.
- ◆ 500 mL graduated cylinder.

D. PRECAUTION

- ◆ Some components in this kit contain a preservative which may cause an allergic skin reaction. Avoid breathing mist.
- ◆ The Stop Solution provided with this kit is an acid solution. Wear protective gloves, clothing, eye, and face protection. Wash hands thoroughly after handling.

VI. PREPARATION

A. SAMPLE COLLECTION AND STORAGE

Cell Culture Supernates - Remove particulates by centrifugation and assay immediately or aliquot and store samples at $\leq -20^{\circ}\text{C}$. Avoid repeated freeze-thaw cycles. Samples may require dilution with Calibrator Diluent (1 \times).

Serum - Use a serum separator tube (SST) and allow samples to clot for 30 minutes at room temperature before centrifugation for 15 minutes at 1000 x g. Remove serum and assay immediately or aliquot and store samples at $\leq -20^{\circ}\text{C}$. Avoid repeated freeze-thaw cycles.

B. SAMPLE PREPARATION

Human serum samples require a 2-fold dilution. A suggested 2-fold dilution is 100 μL of sample + 100 μL of Calibrator Diluent (1 \times).

C. REAGENT PREPARATION

Note: *Bring all reagents to room temperature before use.*

Wash Buffer - If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Dilute 20 mL of Wash Buffer Concentrate (25 \times) into deionized or distilled water to prepare 500 mL of Wash Buffer.

Calibrator Diluent (1 \times) - Use deionized or distilled water to prepare Calibrator Diluent (1 \times).

Reagent Diluent (1 \times) - Use deionized or distilled water to prepare Reagent Diluent (1 \times).

Detection Antibody - **Centrifuge briefly before opening. Reconstitution Volume refer to vial label with Reagent Diluent (1 \times).** Aliquot and store if needed. Dilute stock solution in Reagent Diluent (1 \times) to the working concentration of 8 ng/mL. Prepare at least 15 minutes prior to use.


Streptavidin-HRP B (1 \times) - **Centrifuge briefly before opening.** Dilute to the working concentration specified on the vial label using Reagent Diluent (1 \times).

Human C-Peptide Standard - **Centrifuge briefly before opening. Refer to the vial label for the reconstitution volume***. This reconstitution produces a stock solution of

2000 pg/mL. Allow the standard to sit for a minimum of 15 minutes with gentle agitation prior to making dilutions.

*if you have any question, please seek help from our Technical Support.

Pipette 300 μ L of the appropriate Calibrator Diluent (1 \times) into each tube. Use the stock solution to produce a dilution series (below). Mix each tube thoroughly before the next transfer. The 1000 pg/mL standard serves as the high standard. The Calibrator Diluent (1 \times) serves as the zero standard (0 pg/mL).



D. TECHNICAL HINTS

- When mixing or reconstituting protein solutions, always avoid foaming.
- To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent.
- It is recommended that the samples be pipetted within 15 minutes.
- To ensure accurate results, proper adhesion of plate sealers during incubation steps is necessary.
- TMB Substrate should remain colorless until added to the plate. Keep Substrate Solution protected from light. Substrate Solution should change from colorless to gradations of blue.
- Stop Solution should be added to the plate in the same order as the Substrate Solution. The color developed in the wells will turn from blue to yellow upon addition of the Stop Solution. Wells that are green in color indicate that the Stop Solution has not mixed thoroughly with the Substrate Solution.

VII. ASSAY PROCEDURE

Note: *Bring all reagents and samples to room temperature before use. It is recommended that all samples and standards be assayed in duplicate.*

1. Prepare all reagents and working standards as directed in the previous sections.
2. Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.
3. Add 100 μ L of standard, or prepared sample per well. Cover with the adhesive strip provided. Incubate for 2 hours at room temperature. A plate layout is provided for a record of standards and samples assayed. (Samples may require dilution. See Sample Preparation section.)
4. Aspirate each well and wash, repeating the process three times for a total of four washes. Wash by filling each well with Wash Solution (400 μ L) using a squirt bottle, manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
5. Add 100 μ L of the Detection Antibody diluted in Reagent Diluent, to each well. Cover with a new adhesive strip and incubate 2 hours at room temperature.
6. Repeat the aspiration/wash as in step 4.
7. Add 100 μ L of the working dilution of Streptavidin-HRP B to each well. Cover the plate and incubate for 30 minutes at room temperature. Avoid placing the plate in direct light.
8. Repeat the aspiration/wash as in step 4.
9. Add 100 μ L of TMB Substrate to each well. Incubate for 30 minutes at room temperature. Avoid placing the plate in direct light.
10. Add 50 μ L of Stop Solution to each well. Gently tap the plate to ensure thorough mixing.
11. Determine the optical density of each well within 10 minutes, using a microplate reader set to 450 nm. If wavelength correction is available, set to 540 nm or 570 nm. If wavelength correction is not available, subtract readings at 540 nm or 570 nm from the readings at 450 nm. This subtraction will correct for optical imperfections in

the plate. Readings made directly at 450 nm without correction may be higher and less accurate.

12. **CALCULATION OF RESULTS**

Average the duplicate readings for each standard, control, and sample and subtract the average zero standard optical density (O.D.). Create a standard curve by reducing the data using computer software capable of generating a four parameter logistic (4-PL) curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on the graph. The data may be linearized by plotting the log of the C-Peptide concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data.

If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

VIII. REFERENCES

1. Wahren, J. et al. (2000) *Am. J. Physiol. Endocrinol. Metab.* 278:E759.
2. Hills, C.E. and N.J. Brunskill (2009) *Clin. Sci. (Lond)* 116:565.
3. Gama, R. et al. (2003) *J. Clin. Pathol.* 56:641.
4. Wahren, J. et al. (2012) *Diabetes* 61:761.
5. Rigler, R. et al. (1999) *Proc. Natl. Acad. Sci. USA* 96:13318.
6. Flatt, P.R. et al. (1986) *Biosci. Rep.* 6:193.
7. Al-Rasheed, N.M. et al. (2006) *J. Am. Soc. Nephrol.* 17:986.
8. Nordquist, L. and M. Johansson (2008) *Vasc. Health Risk Manag.* 4:1283.
9. Vasic, D. and D. Walcher (2012) *Mediators Inflamm.* 2012:858692.
10. Forst, T. et al. (2008) *Exp. Diabetes Res.* 2008:176245.
11. Kunt, T. et al. (1999) *Diabetologia* 42:465.
12. Wallerath, T. et al. (2003) *Nitric Oxide* 9:95.
13. Kitamura, T. et al. (2003) *Diabetologia* 46:1698.
14. Ido, Y. et al. (1997) *Science* 277:563.
15. Zhang, W. et al. (2007) *Diabetes Metab. Res. Rev.* 23:63.
16. Rebsomen, L. et al. (2008) *Exp. Diabetes Res.* 2008:281536.

PLATE LAYOUT

Use this plate layout to record standards and samples assayed.

1								
2								
3								
4								
5								
6								
7								
8								
9								
10								
11								
12								
	A	B	C	D	E	F	G	H



产品信息及操作手册

人 C-Peptide Valukine™ ELISA 试剂盒

目录号: **VAL155**

适用于定量检测天然和重组人 C-Peptide 的浓度

科研专用, 不可用于临床诊断

Bio-Techne China Co. Ltd

P: +86 (21) 52380373 P: 8009881270 F: +86 (21) 52381001

info.cn@bio-techne.com

有效期详见试剂盒包装标签

Novus 试剂盒确保在你收货日期 3 个月内有效

目录

I. 背景	18
II. 概述	19
III. 优势	20
IV. 实验	22
V. 试剂盒组成及储存	23
VI. 实验前准备	25
VII. 操作步骤	27
VIII. 参考文献	28

I. 背景

胰岛素是一种肽激素，对葡萄糖稳态至关重要。成熟的胰岛素肽源于胰岛素原，包括由肽片段（C肽）连接的胰岛素A和B链。胰岛素原在胰腺β细胞的内质网内被加工成等摩尔比的成熟胰岛素和C肽。人C肽是一种31个氨基酸（aa）的肽，与小鼠和大鼠蛋白质的氨基酸序列同源性分别为58%和61%。最初，人们认为C肽不具有生物活性；然而，现在的研究表明，它具有促进微血管循环，神经传导和肾功能(1)。在分泌进入门静脉循环后，大量分泌的胰岛素被肝脏迅速代谢。肝脏对C肽的处理可以忽略不计，即可作为胰腺β细胞功能和内源性胰岛素分泌的标志(2, 3)。

C肽以高亲和力特异地和可置换地结合细胞膜，并激活抑制G蛋白（Gi）偶联受体(4-7)。给药C肽可以起到抗炎作用，并可以改善微血管的血流和神经功能(4)。C肽通过下调内皮细胞表面粘附分子，减少炎症细胞因子的产生以及保护血管平滑肌细胞免受有害的胰岛素作用而发挥血管抗炎作用(8)。另外，II型糖尿病患者体内高浓度的C肽可能会导致动脉粥样硬化相关的血管炎症(9)。在糖尿病患者中，服用C肽可致使多组织血流量增加，增强红细胞变形能力(10, 11)。它还激活并上调eNOS，以增加一氧化氮（NO）的合成，已知能引起血管舒张(12, 13)。服用C肽与糖尿病神经病变的改善有关，并可能起到增加神经传导和预防神经功能障碍的作用(14, 15)。此外，C肽可能对糖尿病肾功能起到有益作用(16)。

II. 概述

A. 检测原理

本实验采用双抗体夹心ELISA法。抗人C-Peptide抗体包被于微孔板上，样品和标准品中的人C-Peptide会与固定在板上的抗体结合，游离的成分被洗去；接着加入生物素化的抗人C-Peptide检测抗体进行孵育，洗涤去除未结合的物质后，加入链霉亲和素标记的辣根过氧化物酶(streptavidin-HRP) 孵育。洗涤未结合试剂后，加入TMB底物溶液。溶液颜色与结合的目标蛋白成正比；加入终止液；用酶标仪测定吸光度。

B. 检测局限

- ◆ 仅供科研使用，不可用于体外诊断；
- ◆ 该试剂盒适用于细胞培养上清样本和人血清样本；
- ◆ 请在试剂盒有效期内使用；
- ◆ 不同试剂盒及不同批号试剂盒的组分不能混用；
- ◆ 样本值若大于标准曲线的最高值，应将样本用标准品稀释液（1×）稀释后重新检测；
- ◆ 检测结果的不同可由多种因素引起，包括实验人员的操作、移液器的使用方式、洗板技术、反应时间或温度、试剂盒的储存等。

III. 优势

A. 精确度

板内精确度（同一板内不同孔间的精确度）

已知浓度的三个样本，在同一板内分别检测20次，以确定板内精确度。

板间精确度（不同板之间的精确度）

已知浓度的三个样本，在不同板中分别检测20次，以确定板间精确度。

样本	板内精确度			板间精确度		
	1	2	3	1	2	3
平均值 (pg/mL)	38.5	145.7	499.0	38.2	145.9	510.6
标准差	1.6	6.2	11.6	1.7	6.9	22.7
CV%	4.3	4.3	2.3	4.5	4.7	4.4

B. 回收率

在细胞上清样本中掺入检测范围内不同水平的人C-Peptide，测定其回收率。回收率范围在 96.5-104.7%，平均回收率在100.4%。

在人血清样本中掺入检测范围内不同水平的人C-Peptide，测定其回收率。回收率范围在 83.7-99.7%，平均回收率在92.2%。

C. 灵敏度

人C-Peptide的最低可测剂量（MDD）一般小于0.37pg/mL。

MDD是根据20个重复的零标准品孔的吸光度值的平均值加两倍标准差计算得到的相对应浓度。

D. 校正

此ELISA试剂盒由高纯度重组人C-Peptide蛋白所校正（aa 3-33）。

E. 线性

不同的样本中含有或掺入高浓度的人C-Peptide，然后用标准品稀释液（1×）将样本稀释到检测范围内，测定其线性。

稀释倍数	平均值/期待值 (%)	范围 (%)
1:2	102.5	93.9-115.7
1:4	103.3	94.5-112.2
1:8	110.0	98.2-117.8
1:16	110.5	97.1-120.7

F. 样本预值

血清样本 - 使用本试剂盒检测了6份人血清样本中C-Peptide的水平。6份样本的检测值范围为n.d.-544.8pg/mL。

G. 特异性


将以下因子配置成50ng/mL的浓度来检测没有观察到明显的交叉反应或干扰。

Recombinant human	
IGF-I	Relaxin-1
IGF-II	Relaxin-2
Insulin	Relaxin-3
Insulin R	

IV. 实验

标准曲线实例

该标准曲线数据仅供参考，每次实验应绘制其对应的标准曲线。



V. 试剂盒组成及储存

A. 试剂盒组成

组成	描述	规格
Human C-Peptide Microplate	包被小鼠抗人 C-Peptide 抗体的 96 孔聚苯乙烯板, 8 孔×12 条	1 块板
Human C-Peptide Standard	标准品 (冻干粉), 参考瓶身标签进行重溶	2 瓶
Human C-Peptide Detection antibody	生物素化的 C-Peptide 检测抗体, 冻干粉, 参考瓶身标签进行重溶	1 瓶
Streptavidin-HRP B (40×)	40×浓缩的链霉亲和素标记的 HRP	1 瓶
Reagent Diluent (10×)	浓缩的试剂稀释液 (10×)	1 瓶
Calibrator Diluent (4×)	浓缩的标准品稀释液 (4×)	1 瓶
Wash Buffer Concentrate (25×)	浓缩洗涤缓冲液 (25×)	1 瓶
TMB Substrate	TMB 底物溶液	1 瓶
Stop Solution	终止液	1 瓶
Plate Sealers	封板膜	3 张

B. 试剂盒储存

未开封试剂盒	2-8℃储存；请在试剂盒有效期内使用	
已打开，稀释或重溶的试剂	链霉亲和素-HRP B	2-8℃储存，最多 30 天*
	洗涤缓冲液（1×）	
	TMB 底物溶液	
	终止液	
	标准品	使用时新鲜配制*
	检测抗体	分装，-20℃储存，最多 30 天*
	标准品稀释液（4×）	2-8℃储存，最多 30 天* 请每次使用新鲜配制的 1×标准品稀释液
	试剂稀释液（10×）	2-8℃储存，最多 30 天* 请每次使用新鲜配制的 1×试剂稀释液
包被的微孔板条	将未用的板条放回带有干燥剂的铝箔袋内，密封：2-8℃储存，最多 30 天*	

*必须在试剂盒有效期内

C. 实验所需自备试验器材

- ◆ 酶标仪（可测量450nm检测波长的吸收值及540nm或570nm校正波长的吸收值）
- ◆ 高精度加液器及一次性吸头
- ◆ 去离子水或蒸馏水
- ◆ 洗瓶（喷瓶）、多通道洗板器或自动洗板机
- ◆ 500mL量筒

D. 注意事项

- ◆ 试剂盒中的一些组分含有防腐剂，可能引起皮肤过敏反应，避免吸入。
- ◆ 试剂盒中的终止液是酸性溶液，使用时请做好眼睛、手、面部及衣服的保护。使用后请彻底洗手。

VI. 实验前准备

A. 样品收集及储存

细胞培养上清液：颗粒物应离心去除；立刻检测样本。样本收集后若不及时检测，需按一次使用量分装，冻存于-20℃冰箱内，避免反复冻融。样本可能需要用标准品稀释液（1×）稀释。

血清样本：用血清分离管(SST)分离血清。使血样室温凝集30分钟，然后1000 x g离心15分钟。吸取血清样本之后即刻用于检测，或者分装，-20℃贮存备用。避免反复冻融。

B. 样本准备工作

血清样本需要用标准品稀释液（1×）2倍稀释后进行检测，例如：100μL样本+100μL标准品稀释液（1×）。

C. 检测前准备工作

使用前请将所有试剂放置于室温

洗涤液：从冰箱中取出的浓缩洗涤液可能有结晶，属于正常现象；放置室温，轻摇混匀，待结晶完全溶解后再配制洗涤液。可将20mL浓缩洗涤液用去离子水或蒸馏水稀释配置成500mL工作浓度的洗涤液。

标准品稀释液（1×）：使用去离子水或蒸馏水稀释配置成标准品稀释液（1×）。

试剂稀释液（1×）：使用去离子水或蒸馏水稀释配置成试剂稀释液（1×）。


检测抗体：开盖前请瞬时离心。参考检测抗体瓶标签指示，用试剂稀释液（1×）将冻干粉进行重溶。再用试剂稀释液（1×）稀释至工作浓度8ng/mL，至少在使用前15分钟准备。

链霉亲和素- HRP B：开盖前请瞬时离心。用试剂稀释液（1×）将链霉亲和素- HRP B（40×）稀释至工作浓度链霉亲和素- HRP B（1×）。

C-Peptide标准品：开盖前请瞬时离心。冻干标准品的重溶体积请参考瓶身标签，得到浓度为2000pg/mL标准品母液。轻轻震荡至少15分钟，使其充分溶解。

*如有疑问，请咨询我们的技术支持。

向各稀释管中加入300μL标准品稀释液（1×）。将标准品母液参照下图做系列稀释，每管须充分混匀后再移液到下一管。1000pg/mL管作标准曲线最高点，标准品稀释液（1×）可用作标准品零点（0pg/mL）。



D. 技术小提示

- ◆ 当混合或重溶蛋白液时，尽量避免起沫；
- ◆ 为了避免交叉污染，配置不同浓度标准品、上样、加不同试剂都需要更换枪头。另外不同试剂请分别使用不同的移液槽；
- ◆ 建议15分钟内完成一块板的上样；
- ◆ 每次孵育时，正确使用封板胶纸可保证结果的准确性；
- ◆ TMB底物溶液在上板前应为无色，请避光保存；加入微孔板后，将由无色变成不同深度的蓝色；
- ◆ 终止液上板顺序应同TMB底物溶液上板顺序一致；加入终止液后，孔内颜色由蓝变黄；若孔内有绿色，则表明孔内液体未混匀，请充分混合。

VII. 操作步骤

使用前请将所有试剂和样本放置于室温，建议所有的实验样本和标准品做复孔检测

1. 按照上一节的说明，准备好所有需要的试剂和标准品；
2. 从已平衡至室温的密封袋中取出微孔板，未用的板条请放回铝箔袋内，重新封口；
3. 分别将不同浓度标准品，实验样本或者质控品加入相应孔中，每孔100 μ L。用封板膜封住反应孔，室温孵育2小时。说明书提供了一张96孔模板图，可用于记录标准品和试验样本的板内位置；（样本需要稀释，详情参见样本制备部分。）
4. 将板内液体吸去，使用洗瓶、多通道洗板器或自动洗板机洗板。每孔加洗涤液400 μ L，然后将板内洗涤液吸去。重复操作3次，共洗4次。每次洗板尽量吸去残留液体会有助于得到好的实验结果。最后一次洗板结束，请将板内所有液体吸干或将板倒置，在吸水纸拍干所有残留液体；
5. 在每个微孔内加入100 μ L配置好的检测抗体。用封板胶纸封住反应孔，室温孵育2小时；
6. 重复第4步洗板操作；
7. 在每个微孔内加入100 μ L稀释好的链霉亲和素- HRP B工作液。用封板膜封住反应孔，室温孵育30分钟，**注意避光**；
8. 重复第4步洗板操作；
9. 在每个微孔内加入100 μ L TMB底物溶液，室温孵育30分钟，**注意避光**；
10. 在每个微孔内加入50 μ L终止液，请轻拍微孔板，使溶液混合均匀。孔内溶液颜色会从蓝色变为黄色；
11. 加入终止液后10分钟内，使用酶标仪测量450nm的吸光度值，设定540nm或570nm作为校正波长。如果没有使用双波长校正，结果准确度可能会受影响；
12. **计算结果：**将每个标准品和样品的校正吸光度值（OD₄₅₀-OD₅₄₀/OD₅₇₀），复孔读数取平均值，然后减去平均零标准品OD值。使用计算机软件作四参数逻辑（4-PL）曲线拟合创建标准曲线。另一种方法是，可以通过绘制标准品浓度做对数与相应OD值对数生成曲线，并通过回归分析确定最佳拟合线。通过样本的OD值，可从标准曲线上得到样本中人C-Peptide的浓度。如果样品被稀释，从标准曲线读取的浓度必须乘以稀释倍数。

VIII. 参考文献

1. Wahren, J. et al. (2000) *Am. J. Physiol. Endocrinol. Metab.* 278:E759.
2. Hills, C.E. and N.J. Brunskill (2009) *Clin. Sci. (Lond)* 116:565.
3. Gama, R. et al. (2003) *J. Clin. Pathol.* 56:641.
4. Wahren, J. et al. (2012) *Diabetes* 61:761.
5. Rigler, R. et al. (1999) *Proc. Natl. Acad. Sci. USA* 96:13318.
6. Flatt, P.R. et al. (1986) *Biosci. Rep.* 6:193.
7. Al-Rasheed, N.M. et al. (2006) *J. Am. Soc. Nephrol.* 17:986.
8. Nordquist, L. and M. Johansson (2008) *Vasc. Health Risk Manag.* 4:1283.
9. Vasic, D. and D. Walcher (2012) *Mediators Inflamm.* 2012:858692.
10. Forst, T. et al. (2008) *Exp. Diabetes Res.* 2008:176245.
11. Kunt, T. et al. (1999) *Diabetologia* 42:465.
12. Wallerath, T. et al. (2003) *Nitric Oxide* 9:95.
13. Kitamura, T. et al. (2003) *Diabetologia* 46:1698.
14. Ido, Y. et al. (1997) *Science* 277:563.
15. Zhang, W. et al. (2007) *Diabetes Metab. Res. Rev.* 23:63.
16. Rebsomen, L. et al. (2008) *Exp. Diabetes Res.* 2008:281536.

96 孔模板图

请使用 96 孔模板图来记录标准品及样本在板内的位置

